Merck (MRK) Q2 2026 Earnings Call Transcript
Merck & Co. reported Q2 2026 revenue of $16.6B (+4% ex FX) and a non-GAAP EPS loss of $0.13, tied to a $2.31 one-time charge from its $6.8B Terns Pharmaceuticals acquisition. KEYTRUDA sales were $8.4B. Full-year revenue guidance was raised to $66.3B-$67.3B and EPS to $2.66-$2.76. Merck also cited LIPFENDRA approval and multiple clinical updates.
How this was made
The 30-second read
Why it matters
Traders can update near-term expectations using the explicit full-year revenue and EPS ranges, then stress-test the model around one-time acquisition charges, margin reserve impacts, and expected KEYTRUDA growth moderation. Pipeline readouts and FDA milestones add incremental probability-weighting for future revenue streams.
Market read
This is a primary earnings and guidance disclosure with concrete numbers plus regulatory/clinical catalysts, making it suitable for immediate positioning and model updates.
What to watch
Investors may underweight the magnitude of non-GAAP gross margin decline (inventory reserves) and the 160.3% non-GAAP tax rate, which can affect quality-of-earnings perceptions even if revenue growth remains steady.
Background
Merck’s Q2 2026 earnings call covers revenue/EPS results, full-year guidance, the completed $6.8B Terns Pharmaceuticals acquisition, and multiple clinical and regulatory milestones across oncology, cardiometabolic, immunology, and infectious disease.
Ticker impact
Merck raised and narrowed full-year revenue guidance to $66.3B-$67.3B and EPS to $2.66-$2.76 after the $6.8B Terns acquisition charge.
Near-term volatility likely, with upside bias from guidance raise and WINREVAIR/LIPFENDRA momentum offset by KEYTRUDA growth moderation and margin pressure from inventory reserves.
The article provides explicit guidance ranges, the size/nature of acquisition-related charges, and specific product/regulatory milestones, which are direct inputs to earnings-model revisions and positioning.
Market effects
Biopharma large-cap sentiment may improve as Merck highlights continued oncology demand and expanding cardiometabolic/immunology pipeline execution.
Limited direct regional spillover beyond US large-cap healthcare risk appetite.
Global pharma investors may reprice competitive dynamics in oncology and PCSK9/cardiometabolic categories based on Merck’s uptake and label/approval updates.
Counterpoint
The guidance raise may be partially offset by structurally weaker KEYTRUDA year-over-year comparisons and margin/tax distortions from the Terns one-time charge, limiting sustainable upside.
Key entities
- public_companyMerck & Co., Inc.
Reported Q2 2026 results, raised and narrowed full-year guidance, completed the Terns acquisition, and discussed multiple product and clinical milestones.
- acquired_companyTerns Pharmaceuticals
Acquisition completed for $6.8B, with a $5.7B non-tax-deductible R&D charge impacting non-GAAP EPS guidance.
- productKEYTRUDA
Q2 sales $8.4B, with management warning U.S. growth is expected to moderate as penetration peaks and comparisons get harder.
- productLIPFENDRA
FDA approval secured as a once-daily oral PCSK9 inhibitor, with up to 60% LDL-C reduction cited.
- productWINREVAIR
Q2 sales $588M, up 75% YoY, with a label update establishing a PDUFA date of Sept. 21.
